Fighting Vision Loss: Vabysmo

Use against pair of pathways could pave way for standout in stocked eye disease market.
With Roche/Genentech’s sights set on helping patients suffering from blinding eye conditions, it turned to an innovative bispecific antibody therapy. Vabysmo (faricimab-svoa), the first bispecific antibody approved for the eye, was approved Jan. 28, and analysts expect it will become a blockbuster drug by 2026.

Fighting Vision Loss: Vabysmo (pharmexec.com)